

Twenty-five years' experience of prophylactic treatment

Journal of Internal Medicine

232, 25-32

DOI: [10.1111/j.1365-2796.1992.tb00546.x](https://doi.org/10.1111/j.1365-2796.1992.tb00546.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Prophylaxis: the next haemophilia treatment. <i>Journal of Internal Medicine</i> , 1992, 232, 1-2.	2.7	14
2	Utility of magnetic resonance imaging for management of hemophilic arthropathy in children. <i>Journal of Pediatrics</i> , 1993, 123, 388-392.	0.9	79
3	Transfusion Therapy in Congenital Coagulopathies. <i>Hematology/Oncology Clinics of North America</i> , 1994, 8, 1167-1180.	0.9	5
4	Implantable Intravenous Access Devices in Children With Hemophilia. <i>JAMA Pediatrics</i> , 1994, 148, 327.	3.6	15
5	Pharmacokinetics of factor IX in patients with haemophilia B. <i>European Journal of Clinical Pharmacology</i> , 1994, 46, 325-32.	0.8	64
6	Results of secondary prophylaxis in children with severe hemophilia. <i>American Journal of Hematology</i> , 1994, 47, 113-117.	2.0	156
7	Inhibitors in hemophilia patients: Current status and management. <i>American Journal of Hematology</i> , 1994, 47, 208-217.	2.0	81
8	A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs. <i>Journal of Internal Medicine</i> , 1994, 236, 391-399.	2.7	597
10	Synovectomy for haemophilic arthropathy: 6-21 years of follow-up in 16 patients. <i>Journal of Internal Medicine</i> , 1994, 235, 239-243.	2.7	26
11	Hemophilia A. <i>New England Journal of Medicine</i> , 1994, 330, 38-47.	13.9	398
12	Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 1023-1027.	3.3	113
13	Considerations for current and future management of haemophilia and its complications. <i>Haemophilia</i> , 1995, 1, 2-10.	1.0	37
14	Two decades of haemophilia treatment in the Netherlands, 1972-92. <i>Haemophilia</i> , 1995, 1, 165-171.	1.0	32
15	The impact of prenatal diagnosis on the incidence of haemophilia in Sweden. <i>Haemophilia</i> , 1995, 1, 190-193.	1.0	13
16	Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment. <i>Haemophilia</i> , 1995, 1, 3-7.	1.0	38
17	Haemophilia A management in Victorian, New South Wales and South Australian haemophilia centres. <i>Medical Journal of Australia</i> , 1995, 162, 569-571.	0.8	6
18	Treatment of inherited coagulation disorders. <i>American Journal of Medicine</i> , 1995, 99, 675-682.	0.6	26
19	HEMOPHILIA 1996. <i>Pediatric Clinics of North America</i> , 1996, 43, 709-736.	0.9	24

#	ARTICLE	IF	CITATIONS
20	Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis. <i>Journal of Pediatrics</i> , 1996, 129, 424-431.	0.9	128
21	Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. <i>Blood</i> , 1996, 88, 2603-2610.	0.6	52
22	Why Prescribe Highly Purified Factor VIII and IX Concentrates?. <i>Vox Sanguinis</i> , 1996, 70, 61-68.	0.7	0
23	Orthopaedic Surgery in Hemophilia. <i>Clinical Orthopaedics and Related Research</i> , 1996, 332, 232-241.	0.7	45
24	Effects of Hemophilia on Articulations of Children and Adults. <i>Clinical Orthopaedics and Related Research</i> , 1996, 328, 7-13.	0.7	144
25	Why Prescribe Highly Purified Factor VIII and IX Concentrates?. <i>Vox Sanguinis</i> , 1996, 70, 61-68.	0.7	24
26	Immune Tolerance and the Immune Modulation Protocol. <i>Vox Sanguinis</i> , 1996, 70, 36-41.	0.7	19
27	4 The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. <i>Best Practice and Research: Clinical Haematology</i> , 1996, 9, 259-271.	1.1	19
28	The impact of prophylactic treatment on children with severe haemophilia. <i>British Journal of Haematology</i> , 1996, 92, 973-978.	1.2	192
29	Bedside measurement of factor VIII:C activity in individuals with hemophilia A. , 1996, 51, 181-185.		3
30	Continuous infusion instead of bolus injections of factor concentrate?. <i>Haemophilia</i> , 1996, 2, 189-191.	1.0	6
31	Socioeconomic impact of haemophilia care: results of a pilot study. <i>Haemophilia</i> , 1996, 2, 211-217.	1.0	69
32	Haemophilia.. <i>Postgraduate Medical Journal</i> , 1997, 73, 201-206.	0.9	25
33	Conservative Treatment of Hemarthrosis for Prevention of Hemophilic Synovitis. <i>Clinical Orthopaedics and Related Research</i> , 1997, 343, 12??18.	0.7	35
34	Prophylactic Transfusion for Hypertrophic Synovitis in Children With Hemophilia. <i>Clinical Orthopaedics and Related Research</i> , 1997, 343, 19??24.	0.7	10
35	Current Practice in the Treatment of Haemophilia. <i>Hematology</i> , 1997, 2, 351-358.	0.7	1
36	Pathogenesis, Early Diagnosis, and Prophylaxis for Chronic Hemophilic Synovitis. <i>Clinical Orthopaedics and Related Research</i> , 1997, 343, 6??11.	0.7	11
37	Prophylactic Therapy Programs for Hemophilia in Developing Countries. <i>Pediatric Hematology and Oncology</i> , 1997, 14, ix-xii.	0.3	2

#	ARTICLE	IF	CITATIONS
38	Prophylactic Therapy for Hemophilia in a Developing Country, Turkey. <i>Pediatric Hematology and Oncology</i> , 1997, 14, 151-159.	0.3	14
39	The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products. <i>Transfusion Medicine Reviews</i> , 1997, 11, 6-14.	0.9	11
40	No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products. <i>British Journal of Haematology</i> , 1997, 99, 289-294.	1.2	8
41	Counselling guidelines for managing musculoskeletal problems in haemophilia in the 1990s. <i>Haemophilia</i> , 1997, 3, 9-13.	1.0	15
42	The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. <i>Haemophilia</i> , 1997, 3, 1-8.	1.0	69
43	Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. <i>Journal of Internal Medicine</i> , 1998, 244, 515-522.	2.7	73
44	Well-being of haemophilia patients: a model for direct and indirect effects of medical parameters on the physical and psychosocial functioning. <i>Social Science and Medicine</i> , 1998, 47, 581-593.	1.8	47
45	Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. <i>Annals of Hematology</i> , 1998, 77, 171-174.	0.8	45
46	Distribution and treatment of haemophiliacs. <i>Haemophilia</i> , 1998, 4, 1-2.	1.0	0
47	Approaches to funding: Swedish cost-effectiveness study. <i>Haemophilia</i> , 1998, 4, 10-12.	1.0	0
48	The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994. <i>Haemophilia</i> , 1998, 4, 4-9.	1.0	21
49	The MalmÅr-Klaipeda WFH twinning programme: a comparative description of the Haemophilia cohorts. <i>Haemophilia</i> , 1998, 4, 79-82.	1.0	9
50	Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. <i>Haemophilia</i> , 1998, 4, 83-88.	1.0	59
51	Medical care for haemophilia. <i>Haemophilia</i> , 1998, 4, 806-811.	1.0	5
52	Maintenance of musculoskeletal function in people with haemophilia. <i>Haemophilia</i> , 1998, 4, 26-32.	1.0	17
53	Unsolved problems in haemophilia. <i>Haemophilia</i> , 1998, 4, 341-345.	1.0	15
54	Carrier testing and prenatal diagnosis of haemophilia - utilisation and psychological consequences. <i>Haemophilia</i> , 1998, 4, 365-369.	1.0	13
55	Prophylactic treatment in Sweden - overtreatment or optimal model?. <i>Haemophilia</i> , 1998, 4, 409-412.	1.0	31

#	ARTICLE	IF	CITATIONS
56	When should prophylactic treatment in patients with haemophilia A and B start?- The German experience. <i>Haemophilia</i> , 1998, 4, 413-417.	1.0	148
57	Novel delivery systems for coagulation proteins. <i>Haemophilia</i> , 1998, 4, 436-442.	1.0	16
58	Rehabilitation in haemophilia - options in the developing world. <i>Haemophilia</i> , 1998, 4, 486-490.	1.0	13
59	Functional kinesiology in haemophilia, an area yet to be explored. <i>Haemophilia</i> , 1998, 4, 524-527.	1.0	4
60	Can haemophilic arthropathy be prevented?. <i>British Journal of Haematology</i> , 1998, 101, 215-219.	1.2	49
61	A prospective clinical trial of implantable central venous access in children with haemophilia. <i>British Journal of Haematology</i> , 1998, 102, 1224-1228.	1.2	51
62	Prophylaxis for hemophilia: State of the art or state of confusion?. <i>Journal of Pediatrics</i> , 1998, 132, 915-917.	0.9	7
63	Haldane was right: De novo mutations in androgen insensitivity syndrome. <i>Journal of Pediatrics</i> , 1998, 132, 917-918.	0.9	12
64	Implantable venous access devices in children with hemophilia: A report of low infection rates. <i>Journal of Pediatrics</i> , 1998, 132, 934-938.	0.9	61
65	HEMOPHILIA. <i>Hematology/Oncology Clinics of North America</i> , 1998, 12, 1315-1344.	0.9	55
66	Distribution and treatment of haemophiliacs. <i>Haemophilia</i> , 1998, 4, 1-2.	1.0	57
67	Prophylactic Infusion Regimens in the Management of Hemophilia. <i>Thrombosis and Haemostasis</i> , 1999, 82, 525-530.	1.8	33
68	The Rhesus Macaque as an Animal Model for Hemophilia B Gene Therapy. <i>Blood</i> , 1999, 93, 1875-1881.	0.6	35
69	Assessing health-related quality-of-life in patients with severe haemophilia A and B. <i>Psychology, Health and Medicine</i> , 1999, 4, 5-15.	1.3	32
70	Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. <i>British Journal of Haematology</i> , 1999, 105, 1109-1113.	1.2	258
71	Reproductive choices of haemophilia carriers. <i>British Journal of Haematology</i> , 1999, 106, 421-426.	1.2	28
72	Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. <i>Haemophilia</i> , 1999, 5, 25-32.	1.0	73
73	A retrospective study on chemical and radioactive synovectomy in severe haemophilia patients with recurrent haemarthrosis. <i>Haemophilia</i> , 1999, 5, 115-123.	1.0	71

#	ARTICLE	IF	CITATIONS
76	Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. <i>Histopathology</i> , 1999, 34, 144-153.	1.6	120
77	Persistent expression of canine factor IX in hemophilia B canines. <i>Gene Therapy</i> , 1999, 6, 1695-1704.	2.3	101
79	Joint preserving procedures and endoprotheses in hemophiliacs – indications and long term results. <i>Der Orthopade</i> , 1999, 28, 356-365.	0.7	3
80	Stability and sterility of a recombinant factor viii concentrate prepared for continuous infusion administration. , 1999, 62, 13-18.		11
81	Physiotherapy Management of Haemophilia in Children. , 0, , 169-176.		7
82	Economics of Hemophilia Care. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 333-336.	0.5	2
83	Pulmonary hemorrhage in a hemophiliac simulating a lung neoplasm. <i>American Journal of Hematology</i> , 2000, 64, 299-302.	2.0	7
84	Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome. <i>British Journal of Haematology</i> , 2000, 110, 461-468.	1.2	50
85	Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. <i>Haemophilia</i> , 2000, 6, 23-32.	1.0	154
86	Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. <i>Haemophilia</i> , 2000, 6, 1-10.	1.0	82
87	MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. <i>Haemophilia</i> , 2000, 6, 162-169.	1.0	147
88	The orthopaedic status of severe haemophiliacs in Spain. <i>Haemophilia</i> , 2000, 6, 170-176.	1.0	121
89	Joint evaluation instruments for children and adults with haemophilia. <i>Haemophilia</i> , 2000, 6, 649-657.	1.0	112
90	Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?. <i>Journal of Internal Medicine</i> , 2000, 247, 493-499.	2.7	27
91	Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. <i>Translational Research</i> , 2000, 136, 74-79.	2.4	26
92	Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. <i>Blood</i> , 2000, 96, 1698-1702.	0.6	96
93	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 241-265.	0.9	23
94	Recombinant Coagulation Factor VIIa: From the Concept to Clinical Application in Hemophilia Treatment in 2000. <i>Seminars in Thrombosis and Hemostasis</i> , 2000, Volume 26, 0363-0366.	1.5	69

#	ARTICLE	IF	CITATIONS
95	The Role of Home Infusion Therapy in Haemophilia. <i>Disease Management and Health Outcomes</i> , 2000, 7, 77-81.	0.3	5
96	Pharmacokinetics of Coagulation Factors. <i>Clinical Pharmacokinetics</i> , 2001, 40, 815-832.	1.6	143
97	Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A. <i>New England Journal of Medicine</i> , 2001, 344, 1735-1742.	13.9	360
98	Introduction. <i>Seminars in Hematology</i> , 2001, 38, 1-3.	1.8	2
99	Catheter-related deep venous thrombosis in children with hemophilia. <i>Blood</i> , 2001, 98, 1727-1731.	0.6	108
100	Musculoskeletal pain and functional ability in haemophilia A and B. <i>Physiotherapy and rehabilitation in haemophilia patients. Rheumatology International</i> , 2001, 21, 15-19.	1.5	26
101	Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome. <i>Irish Journal of Medical Science</i> , 2001, 170, 58-58.	0.8	4
102	Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. <i>British Journal of Haematology</i> , 2001, 112, 561-565.	1.2	166
103	Synoviorthesis with radioactive gold in haemophilia. <i>Haemophilia</i> , 2001, 7, 31-33.	1.0	4
104	Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. <i>Haemophilia</i> , 2001, 7, 133-139.	1.0	103
105	Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate. <i>Haemophilia</i> , 2001, 7, 220-223.	1.0	32
106	Motor performance and disability in Dutch children with haemophilia: a comparison with their healthy peers. <i>Haemophilia</i> , 2001, 7, 293-298.	1.0	76
107	Optimal treatment regimens for patients with bleeding disorders. <i>Haemophilia</i> , 2001, 7, 313-320.	1.0	7
108	Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. <i>Haemophilia</i> , 2001, 7, 446-452.	1.0	107
109	Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. <i>Haemophilia</i> , 2001, 7, 517-522.	1.0	75
110	Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters. <i>Haemophilia</i> , 2001, 7, 507-510.	1.0	26
111	Choice of factor concentrates for haemophilia: a developing world perspective. <i>Haemophilia</i> , 2001, 7, 117-122.	1.0	3
112	What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?. <i>Haemophilia</i> , 2001, 7, 99-102.	1.0	7

#	ARTICLE	IF	CITATIONS
113	Methods to treat chronic haemophilic synovitis. <i>Haemophilia</i> , 2001, 7, 1-5.	1.0	7
115	Barriers to compliance with prophylaxis therapy in haemophilia. <i>Haemophilia</i> , 2001, 7, 392-396.	1.0	59
116	Defining the Impact of Hemophilia: The Academic Achievement in Children With Hemophilia Study. <i>Pediatrics</i> , 2001, 108, e105-e105.	1.0	112
117	Early Experience with the Use of Celecoxib in a Child and Adolescent Population. <i>Journal of Pharmacy Practice and Research</i> , 2002, 32, 27-31.	0.5	6
118	Hemophilia A-From Basic Science to Clinical Practice. <i>Seminars in Thrombosis and Hemostasis</i> , 2002, 28, 309-322.	1.5	40
120	Hemophilia gene therapy: Update. <i>Current Opinion in Hematology</i> , 2002, 9, 430-436.	1.2	9
121	Current treatment of hemophilic arthropathy. <i>Current Opinion in Pediatrics</i> , 2002, 14, 46-49.	1.0	68
122	The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. <i>Blood</i> , 2002, 99, 2337-2341.	0.6	245
123	32P Radiosynoviorthesis in Children With Hemophilia. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 534-539.	0.3	64
124	Pain coping strategies among patients with haemophilia. <i>Psychology, Health and Medicine</i> , 2002, 7, 271-281.	1.3	10
125	Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia. <i>Pharmacoeconomics</i> , 2002, 20, 759-774.	1.7	62
126	State of Care for Hemophilia in Pediatric Patients. <i>Paediatric Drugs</i> , 2002, 4, 149-157.	1.3	20
127	Treatment Strategies in Children with Hemophilia. <i>Paediatric Drugs</i> , 2002, 4, 427-437.	1.3	15
128	Radionuclide Synovectomy for Hemophilic Arthropathy: A Comprehensive Review of Safety and Efficacy and Recommendation for a Standardized Treatment Protocol. <i>Thrombosis and Haemostasis</i> , 2002, 87, 383-393.	1.8	67
129	Total knee arthroplasty in patients with severe haemophilia. <i>International Orthopaedics</i> , 2002, 26, 89-91.	0.9	10
130	Orthopaedic surgery of haemophilia in the 21st century: an overview. <i>Haemophilia</i> , 2002, 8, 360-368.	1.0	33
131	Clinical outcomes and resource utilization associated with haemophilia care in Europe. <i>Haemophilia</i> , 2002, 8, 33-43.	1.0	98
132	Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. <i>Haemophilia</i> , 2002, 8, 44-50.	1.0	168

#	ARTICLE	IF	CITATIONS
133	Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia, 2002, 8, 98-103.	1.0	73
134	Haemophilia Utilization Group Study: assessment of functional health status in haemophilia. Haemophilia, 2002, 8, 121-128.	1.0	12
135	Evaluation of outcome of care in patients with haemophilia. Haemophilia, 2002, 8, 428-434.	1.0	32
136	Prophylaxis in developed and in emerging countries. Haemophilia, 2002, 8, 183-188.	1.0	17
137	Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia, 2002, 8, 76-82.	1.0	68
138	Linking medicine and economics: health economics and quality of life in haemophilia care. Haemophilia, 2002, 8, 217-220.	1.0	7
139	Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors. Haemophilia, 2002, 8, 706-710.	1.0	18
140	Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy. Haemophilia, 2002, 8, 832-833.	1.0	5
142	Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure. Haemophilia, 2002, 8, 809-814.	1.0	12
143	Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia, 2002, 8, 753-760.	1.0	147
144	Aspects of haemophilia prophylaxis in Sweden. Haemophilia, 2002, 8, 34-37.	1.0	17
145	Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia, 2002, 8, 43-46.	1.0	42
146	The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency. British Journal of Haematology, 2002, 119, 789-791.	1.2	32
147	Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Quality of Life Research, 2002, 11, 127-133.	1.5	59
149	Value of magnetic resonance imaging for the diagnosis and follow-up of haemophilic arthropathy. Haemophilia, 2003, 9, 76-85.	1.0	56
150	The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia, 2003, 9, 38-49.	1.0	165
151	Analgesic use and pain coping among patients with haemophilia. Haemophilia, 2003, 9, 202-213.	1.0	35
152	Experience with a new percutaneous port system, Percuseal [®] , for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1 -antitrypsin deficiency. Haemophilia, 2003, 9, 173-178.	1.0	8

#	ARTICLE	IF	CITATIONS
153	Prophylaxis in factor IX deficiency product and patient variation. Haemophilia, 2003, 9, 279-284.	1.0	41
154	The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia, 2003, 9, 272-278.	1.0	80
155	The pharmacokinetics of clotting factor therapy. Haemophilia, 2003, 9, 353-359.	1.0	53
156	Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia, 2003, 9, 376-381.	1.0	57
157	Factor replacement therapy in haemophilia - are there models for developing countries?. Haemophilia, 2003, 9, 391-396.	1.0	32
158	Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia, 2003, 9, 251-260.	1.0	41
160	Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia, 2003, 9, 521-540.	1.0	64
161	Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia, 2003, 9, 549-554.	1.0	34
162	On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia, 2003, 9, 555-566.	1.0	111
163	When to start and when to stop primary prophylaxis in patients with severe haemophilia. Haemophilia, 2003, 9, 32-37.	1.0	21
164	Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia, 2003, 9, 57-64.	1.0	67
165	A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia, 2003, 9, 19-26.	1.0	65
166	Economics of prophylactic treatment. Haemophilia, 2003, 9, 111-116.	1.0	24
167	North American prophylaxis studies for persons with severe haemophilia: background, rationale and design. Haemophilia, 2003, 9, 44-49.	1.0	24
168	How to start prophylaxis. Haemophilia, 2003, 9, 83-87.	1.0	20
169	A global view on prophylaxis: possibilities and consequences. Haemophilia, 2003, 9, 10-18.	1.0	17
170	Prophylactic therapy for haemophilia: early experience. Haemophilia, 2003, 9, 5-9.	1.0	17
171	Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia, 2003, 9, 101-110.	1.0	90

#	ARTICLE	IF	CITATIONS
172	Adverse events in the prophylaxis of haemophilia. <i>Haemophilia</i> , 2003, 9, 50-56.	1.0	15
173	Prospective controlled studies on prophylaxis: an Italian approach. <i>Haemophilia</i> , 2003, 9, 38-43.	1.0	41
174	Factor concentrate usage in persons with hemophilia in New York State. <i>Transfusion</i> , 2003, 43, 470-475.	0.8	9
175	Haemophilias A and B. <i>Lancet, The</i> , 2003, 361, 1801-1809.	6.3	650
176	Introduction: Hemophilia treatment today. <i>Seminars in Hematology</i> , 2003, 40, 1-2.	1.8	0
177	Update on treatment regimens: Prophylaxis versus on-demand therapy. <i>Seminars in Hematology</i> , 2003, 40, 3-9.	1.8	22
179	The Illness Perceptions and Treatment Beliefs of Individuals with Severe Haemophilia and their Role in Adherence to Home Treatment. <i>Psychology and Health</i> , 2003, 18, 185-200.	1.2	92
180	A Healthy Hemophilic Patient without Arthropathy: From Concept to Clinical Reality. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 005-010.	1.5	11
181	Prophylaxis for Severe Hemophilia: Experience from Europe and the United States. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 049-054.	1.5	25
182	Orthopedic Outcome Studies and Cost Issues. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 055-060.	1.5	4
183	Advances in Care of Children with Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 585-594.	1.5	46
184	Arthroscopic Synovectomy in Children and Adolescents With Hemophilia. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 726-731.	0.3	58
185	Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. <i>Blood</i> , 2003, 102, 2038-2045.	0.6	210
186	Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. <i>Blood</i> , 2003, 102, 4393-4398.	0.6	40
187	Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. <i>Blood</i> , 2003, 102, 4006-4013.	0.6	143
188	Orthopaedic care in haemophilia. <i>British Journal of Hospital Medicine</i> , 2003, 64, 68-69.	0.3	0
190	Orthopaedic surgery in persons with haemophilia. <i>Thrombosis and Haemostasis</i> , 2003, 89, 34-42.	1.8	23
191	The Haemophilic Shoulder. , 0, , 163-166.		3

#	ARTICLE	IF	CITATIONS
194	The Bleeding Child: Congenital and Acquired Disorders. , 2004, , 221-244.		1
195	Challenges for Social Work in Hemophilia Care. Health and Social Work, 2004, 29, 149-152.	0.5	4
196	Outcome measures in haemophilia: more than just factor levels. Haemophilia, 2004, 10, 2-8.	1.0	17
197	Economic evaluation: what are we looking for and how do we get there?. Haemophilia, 2004, 10, 44-49.	1.0	10
198	Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia. Haemophilia, 2004, 10, 58-62.	1.0	13
199	Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. British Journal of Haematology, 2004, 126, 565-573.	1.2	29
200	Dose and response in haemophilia - optimization of factor replacement therapy. British Journal of Haematology, 2004, 127, 12-25.	1.2	46
201	Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?. Haemophilia, 2004, 10, 147-157.	1.0	63
202	A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia, 2004, 10, 383-389.	1.0	92
203	FEIBAR safety profile in multiple modes of clinical and home-therapy application. Haemophilia, 2004, 10, 10-16.	1.0	72
204	Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia, 2004, 10, 515-526.	1.0	39
205	Optimizing factor prophylaxis for the haemophilia population: where do we stand?. Haemophilia, 2004, 10, 97-104.	1.0	85
206	A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia, 2004, 10, 689-697.	1.0	140
207	A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia, 2004, 10, 679-683.	1.0	29
208	Dose and outcome of care in haemophilia - how do we define cost-effectiveness?. Haemophilia, 2004, 10, 216-220.	1.0	19
209	Prophylactic factor replacement in hemophilia. Blood Reviews, 2004, 18, 101-113.	2.8	45
210	Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. Haemophilia, 2004, 10, 18-26.	1.0	19
211	Home management of haemophilia. Haemophilia, 2004, 10, 118-133.	1.0	100

#	ARTICLE	IF	CITATIONS
212	Prevention of bleeds in hemophilia patients with inhibitors: Emerging data and clinical direction. American Journal of Hematology, 2004, 77, 187-193.	2.0	86
213	Recent advances in the management of the child who has hemophilia. Hematology/Oncology Clinics of North America, 2004, 18, 1249-1276.	0.9	13
214	Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. Journal of Pediatrics, 2004, 145, 628-634.	0.9	39
215	An approach to target joint bleeding in hemophilia: Prophylaxis for all or individualized treatment?. Journal of Pediatrics, 2004, 145, 581-583.	0.9	6
216	Treatment of Hemophilia With Genetic Engineering. Transfusion Alternatives in Transfusion Medicine, 2004, 6, 46-54.	0.2	1
217	Long-term aspects of hemophilia B treatment. Blood Coagulation and Fibrinolysis, 2004, 15, S11-S13.	0.5	3
218	Bioengineering of coagulation factor VIII for improved secretion. Blood, 2004, 103, 3412-3419.	0.6	193
219	Long-term prophylaxis in von Willebrand disease. Blood Coagulation and Fibrinolysis, 2005, 16, S23-S26.	0.5	106
220	Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagulation and Fibrinolysis, 2005, 16, 477-485.	0.5	40
222	International Forum. Vox Sanguinis, 2005, 88, 63-64.	0.7	0
224	MRI scores of ankle joints in children with haemophilia - comparison with clinical data. Haemophilia, 2005, 11, 116-122.	1.0	68
225	Changing pattern of care of boys with haemophilia in western European centres. Haemophilia, 2005, 11, 92-99.	1.0	53
226	An exploration of health-related quality of life in adults with haemophilia - a qualitative perspective. Haemophilia, 2005, 11, 123-132.	1.0	55
227	Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia, 2005, 11, 270-275.	1.0	25
228	Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia, 2005, 11, 240-244.	1.0	34
229	The effect of clotting factor concentrates on the immune system in HIV-negative haemophiliacs. Haemophilia, 2005, 11, 366-370.	1.0	3
230	Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia, 2005, 11, 438-443.	1.0	125
231	Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia, 2005, 11, 598-602.	1.0	92

#	ARTICLE	IF	CITATIONS
232	Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. <i>British Journal of Haematology</i> , 2005, 130, 107-112.	1.2	90
233	Endpoints in clinical trials involving hemostasis and bleeding in patients with hemophilia. <i>Transfusion</i> , 2005, 45, 2S-3S.	0.8	0
234	Care of the Child with Hemophilia. , 0, , 120-124.		1
235	Products used to Treat Hemophilia: Recombinant Factor VIIa. , 0, , 147-152.		3
236	Quality of Life in Hemophilia. , 0, , 345-350.		4
237	The Economics of Hemophilia Treatments. , 0, , 351-358.		2
238	Comprehensive Care and Delivery of Care: The Developing World. , 0, , 366-370.		2
239	Prophylaxis. , 0, , 39-45.		1
240	Hemophilia Orthopedic Management with Emphasis on Developing Countries. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 518-526.	1.5	22
242	Therapy for haemophilia: recent advances and goals for the future. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 173-184.	1.0	16
243	Congenital bleeding disorders. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2005, 35, 38-62.	0.8	40
244	Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura. <i>Pharmacoeconomics Italian Research Articles</i> , 2006, 8, 33-44.	0.2	1
245	Functional Assessment of Arthropathy—An International Perspective. <i>Seminars in Hematology</i> , 2006, 43, S27-S32.	1.8	22
246	Surgery in Hemophilia. The General View: Patient Selection, Timing, and Preoperative Assessment. <i>Seminars in Hematology</i> , 2006, 43, S23-S26.	1.8	28
248	Physical Activity and Type 2 Diabetes Mellitus. <i>The Journal of Korean Diabetes Association</i> , 2006, 30, 1.	0.1	3
249	Exercise, Metabolic Syndrome and Type 2 Diabetes. , 2006, , 77-93.		0
250	Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. <i>Blood</i> , 2006, 108, 3668-3673.	0.6	58
252	How well does the Canadian haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia?. <i>Pediatric Blood and Cancer</i> , 2006, 47, 305-311.	0.8	66

#	ARTICLE	IF	CITATIONS
253	More on: are randomized clinical trials the only truth? Not always. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1167-1168.	1.9	6
254	Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1228-1236.	1.9	224
255	Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2498-2500.	1.9	31
256	Optimal haemophilia care versus the reality. <i>British Journal of Haematology</i> , 2006, 132, 671-682.	1.2	59
257	Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. <i>British Journal of Haematology</i> , 2006, 132, 798-799.	1.2	9
258	Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. <i>Haemophilia</i> , 2006, 12, 82-86.	1.0	10
259	Practice patterns in haemophilia A therapy - global progress towards optimal care. <i>Haemophilia</i> , 2006, 12, 75-81.	1.0	153
260	Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. <i>Haemophilia</i> , 2006, 12, 47-51.	1.0	103
261	Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. <i>Haemophilia</i> , 2006, 12, 241-247.	1.0	88
262	Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. <i>Haemophilia</i> , 2006, 12, 159-168.	1.0	44
263	Hemophilia joint health score reliability study. <i>Haemophilia</i> , 2006, 12, 518-525.	1.0	273
264	Retrospective comparative examination of the long term effects of venous access devices on upper extremity limb measurement in children with haemophilia: pilot observations from a single haemophilia treatment centre. <i>Haemophilia</i> , 2006, 12, 526-530.	1.0	5
265	Clinical pharmacokinetic studies on factor VIII and factor IX - experiences from the Malmö centre. <i>Haemophilia</i> , 2006, 12, 12-14.	1.0	0
266	Factor VIII pharmacokinetics: impact of low titer non-neutralizing inhibitors and use in determination of successful immune tolerance. <i>Haemophilia</i> , 2006, 12, 56-60.	1.0	3
267	Prophylaxis in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2006, 12, 67-73.	1.0	24
268	FEIBA prophylaxis for patients with haemophilia and inhibitors. <i>Haemophilia</i> , 2006, 12, 26-31.	1.0	24
270	Prophylaxis and Treatment of Bleeding Complications in von Willebrand Disease Type 3. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 621-625.	1.5	21
271	Managing the Pediatric Patient and the Adolescent/Adult Transition. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 028-031.	1.5	3

#	ARTICLE	IF	CITATIONS
272	Hemophilia A and B. , 0, , 583-597.		0
273	Current Issues in Prophylactic Therapy for Persons with Hemophilia. <i>Acta Haematologica</i> , 2006, 115, 162-171.	0.7	21
274	Kogenate®FS: antihemophilic factor rFVIII-FS. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 699-708.	0.2	1
275	Gadolinium contrast agent is of limited value for magnetic resonance imaging assessment of synovial hypertrophy in hemophiliacs. <i>Acta Radiologica</i> , 2007, 48, 520-530.	0.5	25
276	Transfusion of the Patient with Congenital Coagulation Defects. , 2007, , 467-481.		3
277	Haemophilia A: meeting the needs of individual patients. <i>British Journal of Nursing</i> , 2007, 16, 987-993.	0.3	4
278	Prophylactic Treatment for Prevention of Joint Disease in Hemophilia – Cost versus Benefit. <i>New England Journal of Medicine</i> , 2007, 357, 603-605.	13.9	43
279	Central Venous Access Device Infections in Children With Hemophilia. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 458-464.	0.3	16
280	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. <i>New England Journal of Medicine</i> , 2007, 357, 535-544.	13.9	1,681
281	Arteriovenous fistula for long-term venous access for boys with hemophilia. <i>Journal of Vascular Surgery</i> , 2007, 45, 986-991.	0.6	23
282	Prophylactic treatment with activated prothrombin complex concentrate (FEIBA [®] 1/2) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. <i>Haemophilia</i> , 2007, 13, 249-255.	1.0	64
283	Prophylaxis in the haemophilia population-optimizing therapy. <i>Haemophilia</i> , 2007, 13, 227-232.	1.0	6
284	Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment options. <i>Haemophilia</i> , 2007, 13, 1-3.	1.0	6
285	Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. <i>Haemophilia</i> , 2007, 13, 10-15.	1.0	19
286	Liposomal approach towards the development of a longer-acting factor VIII. <i>Haemophilia</i> , 2007, 13, 23-28.	1.0	18
287	Psychometric analysis of the Functional Independence Score in Haemophilia (FISH). <i>Haemophilia</i> , 2007, 13, 620-626.	1.0	65
288	European Study on Orthopaedic Status of haemophilia patients with inhibitors. <i>Haemophilia</i> , 2007, 13, 606-612.	1.0	192
289	Prevention of haemophilic synovitis: prophylaxis. <i>Haemophilia</i> , 2007, 13, 20-25.	1.0	7

#	ARTICLE	IF	CITATIONS
290	Optimizing outcomes for patients with severe haemophilia A. <i>Haemophilia</i> , 2007, 13, 1-16.	1.0	235
292	Protecting the joints of mice and men. <i>Haemophilia</i> , 2008, 14, 117-118.	1.0	2
293	Modern management of haemophilic arthropathy. <i>British Journal of Haematology</i> , 2007, 136, 777-787.	1.2	105
294	Phenotypic heterogeneity in severe hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 151-156.	1.9	106
295	Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1904-1913.	1.9	320
296	Port-A-Cath usage in children with haemophilia: experience of 53 cases. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007, 87, 1051-1054.	0.7	73
297	Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2002, 91, 910-914.	0.7	29
298	Ex Vivo Gene Therapy for Hemophilia A That Enhances Safe Delivery and Sustained In Vivo Factor VIII Expression from Lentivirally Engineered Endothelial Progenitors. <i>Stem Cells</i> , 2007, 25, 2660-2669.	1.4	98
299	Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 969-975.	1.9	33
300	Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1319-1326.	1.9	134
301	Activity and regulation of glycoPEGylated factor VIIa analogs. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1525-33.	1.9	13
302	Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2048-2054.	1.9	74
303	Intracranial haemorrhage in haemophilia A and B. <i>British Journal of Haematology</i> , 2008, 140, 378-384.	1.2	162
304	Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience. <i>Haemophilia</i> , 2008, 14, 260-270.	1.0	22
305	Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. <i>Haemophilia</i> , 2008, 14, 466-475.	1.0	85
306	Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. <i>Haemophilia</i> , 2008, 14, 743-752.	1.0	64
307	Back to the future: a recent history of haemophilia treatment. <i>Haemophilia</i> , 2008, 14, 10-18.	1.0	137
308	Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. <i>Haemophilia</i> , 2008, 14, 196-201.	1.0	34

#	ARTICLE	IF	CITATIONS
309	Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG<scp>)/</scp>. Haemophilia, 2008, 14, 162-169.	1.0	62
310	Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia, 2008, 14, 945-951.	1.0	124
311	The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia, 2008, 14, 923-930.	1.0	96
312	Prevention of haemophilic arthropathy in haemophilic children with inhibitors. Haemophilia, 2008, 14, 1-3.	1.0	76
313	Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment. Haemophilia, 2008, 14, 4-10.	1.0	56
314	Prevention of arthropathy in haemophilia: prophylaxis. Haemophilia, 2008, 14, 16-19.	1.0	12
315	Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?. Haemophilia, 2008, 14, 23-27.	1.0	7
316	Experiences in the prevention of arthropathy in haemophilia patients with inhibitors. Haemophilia, 2008, 14, 28-35.	1.0	12
317	The role of rehabilitation and sports in haemophilia patients with inhibitors. Haemophilia, 2008, 14, 45-51.	1.0	21
318	Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?. Haemophilia, 2008, 14, 68-81.	1.0	49
319	Orthopedic Management in Hemophilia: A Spanish Outlook. Seminars in Hematology, 2008, 45, S58-S63.	1.8	7
320	Blood-Induced Joint Disease: The Confluence of Dysregulated Oncogenes, Inflammatory Signals, and Angiogenic Cues. Seminars in Hematology, 2008, 45, S50-S57.	1.8	33
321	Management of hemophilia in resourceâ€limited countries. Transfusion Alternatives in Transfusion Medicine, 2008, 10, 70-74.	0.2	5
323	Assessment of Treatment Practice Patterns for Severe Hemophilia A: A Global Nurse Perspective. Acta Haematologica, 2008, 119, 115-123.	0.7	40
325	Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Thrombosis and Haemostasis, 2008, 99, 71-76.	1.8	18
326	Potential role of prophylactic treatment for prevention of joint disease in hemophilia A. Pediatric Health, 2008, 2, 17-19.	0.3	0
327	Avoiding the Impact of Musculoskeletal Pain on Quality of Life in Children With Hemophilia. Orthopaedic Nursing, 2008, 27, 103-108.	0.2	16
328	Prophylaxis in people with haemophilia. Thrombosis and Haemostasis, 2009, 101, 674-681.	1.8	61

#	ARTICLE	IF	CITATIONS
329	Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. <i>Biologics: Targets and Therapy</i> , 0, , 117.	3.0	1
330	Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 584-587.	0.2	16
331	Need for Prophylactic Treatment in Adult Haemophilia A Patients. <i>Transfusion Medicine and Hemotherapy</i> , 2009, 36, 283-288.	0.7	5
332	Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 273-283.	1.4	31
333	Pharmacokinetic dosing in prophylactic treatment of hemophilia A. <i>European Journal of Haematology</i> , 1993, 51, 247-252.	1.1	110
334	Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. <i>Haemophilia</i> , 2009, 15, 78-82.	1.0	16
335	Thrombin generation assay: a useful routine checkâ€ tool in the management of patients with haemophilia?. <i>Haemophilia</i> , 2009, 15, 290-296.	1.0	29
336	Longâ€ term prophylaxis in severe haemophilia seems to preserve bone mineral density. <i>Haemophilia</i> , 2009, 15, 261-266.	1.0	53
337	Haemophilia, aging and sexuality. <i>Haemophilia</i> , 2009, 15, 55-62.	1.0	21
338	Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. <i>Haemophilia</i> , 2009, 15, 203-209.	1.0	55
339	von Willebrand disease in the 21st century: current approaches and new challenges. <i>Haemophilia</i> , 2009, 15, 1154-1158.	1.0	11
340	Haemophilia care in children â€ benefits of early prophylaxis for inhibitor prevention. <i>Haemophilia</i> , 2009, 15, 8-14.	1.0	27
341	Forum on: the role of recombinant factor VIII in children with severe haemophilia A. <i>Haemophilia</i> , 2009, 15, 578-586.	1.0	20
342	The benefits of prophylactic treatment with APCC in patients with haemophilia and highâ€ titre inhibitors: a retrospective case series. <i>Haemophilia</i> , 2009, 15, 733-742.	1.0	37
343	Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. <i>Haemophilia</i> , 2009, 15, 983-989.	1.0	35
344	Revisiting the costâ€ effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. <i>Haemophilia</i> , 2009, 15, 881-887.	1.0	44
345	Healthâ€ related quality of life and productivity impact in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2009, 15, 911-917.	1.0	58
346	Assessment of haemophilia treatment practice pattern in Japan. <i>Haemophilia</i> , 2009, 15, 1032-1038.	1.0	12

#	ARTICLE	IF	CITATIONS
347	Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. <i>Haemophilia</i> , 2009, 15, 1219-1227.	1.0	61
348	Hemophilia severity score system: validation from an Italian Regional Hemophilia Reference Center. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 720-722.	1.9	11
349	Prophylactic therapy in haemophilia. <i>Blood Reviews</i> , 2009, 23, 267-274.	2.8	49
351	Epidemiological survey of haemophiliacs with inhibitors in France: orthopaedic status, quality of life and cost - the "Statut Orthopédique des Patients Hémothésiques" avec Inhibiteur study. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 4-11.	0.5	16
352	3. Hemophilia and Von Willebrand's Disease- Focus on Replacement Therapy. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2009, 98, 1608-1618.	0.0	1
353	Congenital Disorders of Clotting Proteins and Hypercoagulable States in Pediatrics. , 0, , 426-447.		0
354	Bacterial Endocarditis and Septic Arthritis in a Patient With Severe Hemophilia A. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 344-345.	0.3	7
356	Improvements in factor concentrates. <i>Current Opinion in Hematology</i> , 2010, 17, 393-397.	1.2	34
363	Enabling normal psychophysical development in children with hemophilia: the choice for prophylaxis. <i>Pediatric Health</i> , 2010, 4, 183-199.	0.3	1
364	Musculoskeletal Complications of Hemophilia. <i>HSS Journal</i> , 2010, 6, 37-42.	0.7	96
365	Treatment of hemophilia in developing countries: A journey of a thousand miles. <i>Pediatric Blood and Cancer</i> , 2010, 54, 348-349.	0.8	3
366	Efficacy and safety of secondary prophylactic vs. on-demand sucrose formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 83-89.	1.9	129
367	To bleed or not to bleed - is that a question?. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 81-82.	1.9	1
368	Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 269-275.	1.9	176
369	Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 730-736.	1.9	115
370	Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 737-743.	1.9	187
371	Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1256-1265.	1.9	242
372	Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B. <i>Haemophilia</i> , 1996, 2, 137-140.	1.0	31

#	ARTICLE	IF	CITATIONS
373	FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. <i>Haemophilia</i> , 2010, 16, 80-89.	1.0	24
374	Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. <i>Haemophilia</i> , 2010, 16, 90-100.	1.0	47
375	Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2010, 16, 263-271.	1.0	46
376	Safety and efficacy of investigator-prescribed BeneFIX [®] prophylaxis in children less than 6 years of age with severe haemophilia B. <i>Haemophilia</i> , 2010, 16, 460-468.	1.0	44
377	Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania. <i>Haemophilia</i> , 2010, 16, 479-486.	1.0	26
378	Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis. <i>Haemophilia</i> , 2010, 16, 495-501.	1.0	41
379	Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. <i>Haemophilia</i> , 2010, 16, 597-605.	1.0	98
380	Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. <i>Haemophilia</i> , 2010, 16, 4-9.	1.0	15
381	Meeting unmet needs in inhibitor patients. <i>Haemophilia</i> , 2010, 16, 46-51.	1.0	16
382	The challenge of an ageing haemophilic population. <i>Haemophilia</i> , 2010, 16, 11-16.	1.0	46
383	Special lectures in haemophilia management. <i>Haemophilia</i> , 2010, 16, 22-28.	1.0	10
384	Prophylaxis in the haemophilia population. <i>Haemophilia</i> , 2010, 16, 181-188.	1.0	62
385	The role of prophylaxis in bleeding disorders. <i>Haemophilia</i> , 2010, 16, 189-193.	1.0	11
386	A United Kingdom Haemophilia Centre Doctors [™] Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. <i>British Journal of Haematology</i> , 2010, 149, 498-507.	1.2	123
387	Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. <i>Vascular Health and Risk Management</i> , 2010, 6, 59.	1.0	12
388	Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors. <i>Journal of Blood Medicine</i> , 2010, 1, 37.	0.7	1
389	Treatment of hemophilia: a review of current advances and ongoing issues. <i>Journal of Blood Medicine</i> , 2010, 1, 183.	0.7	89
390	Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 780-790.	1.5	40

#	ARTICLE	IF	CITATIONS
391	Novel drugs to treat hemophilia. Expert Opinion on Emerging Drugs, 2010, 15, 597-613.	1.0	7
392	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. The Cochrane Library, 2011, , CD003429.	1.5	92
393	Pharmacotherapy of haemophilia A. Expert Opinion on Biological Therapy, 2011, 11, 1039-1053.	1.4	3
394	Haemophilia and Joint Disease: Pathophysiology, Evaluation, and Management. Journal of Comorbidity, 2011, 1, 51-59.	3.9	111
395	Haemophilia B: impact on patients and economic burden of disease. Thrombosis and Haemostasis, 2011, 106, 398-404.	1.8	54
396	Hypercalciuria in children with haemophilia suggests primary skeletal pathology. British Journal of Haematology, 2011, 153, 364-371.	1.2	20
397	Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia, 2011, 17, 70-74.	1.0	89
398	First 20 years with recombinant FVIIa (NovoSeven). Haemophilia, 2011, 17, e172-82.	1.0	67
399	Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan. Haemophilia, 2011, 17, 45-54.	1.0	14
400	Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia, 2011, 17, 2-10.	1.0	170
401	Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre. Haemophilia, 2011, 17, 228-232.	1.0	3
402	Bone density and health-related quality of life in adult patients with severe haemophilia. Haemophilia, 2011, 17, 304-311.	1.0	28
403	Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery. Haemophilia, 2011, 17, 428-432.	1.0	4
404	Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia, 2011, 17, 433-438.	1.0	41
405	Recombinant factor concentrates may increase inhibitor development: a single centre cohort study. Haemophilia, 2011, 17, 625-629.	1.0	27
406	When should prophylaxis therapy in inhibitor patients be considered?. Haemophilia, 2011, 17, e849-57.	1.0	26
407	Reduced early prophylaxis of children with haemophilia in a developing country, Turkey. Haemophilia, 2011, 17, e840-1.	1.0	5
408	Joint protection in haemophilia. Haemophilia, 2011, 17, 1-23.	1.0	107

#	ARTICLE	IF	CITATIONS
409	Treatment of haemophilia: building on strength in the third millennium. <i>Haemophilia</i> , 2011, 17, 1-24.	1.0	16
410	A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 700-710.	1.9	390
411	Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1067-1069.	1.9	24
412	Prophylaxis in haemophilia and other inherited bleeding disorders. <i>ISBT Science Series</i> , 2011, 6, 172-175.	1.1	0
413	Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. <i>Blood</i> , 2011, 118, 2695-2701.	0.6	178
414	Clinical advances in hemophilia management. <i>Pediatric Blood and Cancer</i> , 2011, 57, 910-920.	0.8	3
415	Cell Phones and Landlines: The Impact of Gene Therapy on the Cost and Availability of Treatment for Hemophilia. <i>Molecular Therapy</i> , 2011, 19, 1749-1750.	3.7	16
416	Equipoise should be amended, not abandoned. <i>Clinical Trials</i> , 2011, 8, 408-416.	0.7	39
417	Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2082-2087.	3.3	51
418	Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. <i>Therapeutic Advances in Drug Safety</i> , 2011, 2, 213-225.	1.0	15
419	Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial. <i>Expert Review of Hematology</i> , 2011, 4, 495-507.	1.0	7
420	Recombinant FIXFc: a novel therapy for the royal disease?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1361-1368.	1.4	11
421	Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors. <i>Journal of Blood Medicine</i> , 2012, 3, 17.	0.7	9
422	New treatments in hemophilia: insights for the clinician. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 165-175.	1.1	12
423	Radionuclide Therapy for Bleeding Joints in Hemophilia. <i>Medical Radiology</i> , 2012, , 495-502.	0.0	0
424	Prophylaxis in Children with Hemophilia: Evidence-Based Achievements, Old and New Challenges. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 79-94.	1.5	74
425	The Diagnosis and Management of Congenital Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 727-734.	1.5	75
426	A complex substitute: antibody therapy for hemophilia. <i>Nature Medicine</i> , 2012, 18, 1460-1461.	15.2	2

#	ARTICLE	IF	CITATIONS
427	Attacking the flank: targeting new pathways in SBMA. <i>Nature Medicine</i> , 2012, 18, 1461-1463.	15.2	2
428	Prevention of the Musculoskeletal Complications of Hemophilia. <i>Advances in Preventive Medicine</i> , 2012, 2012, 1-7.	1.1	37
429	Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. <i>Blood</i> , 2012, 119, 3031-3037.	0.6	215
430	Modern haemophilia care. <i>Lancet, The</i> , 2012, 379, 1447-1456.	6.3	266
431	Management of joint bleeding in hemophilia. <i>Expert Review of Hematology</i> , 2012, 5, 459-468.	1.0	48
432	How we choose factor VIII to treat hemophilia. <i>Blood</i> , 2012, 119, 4108-4114.	0.6	74
433	Hemophilia management in transfusion medicine. <i>Transfusion and Apheresis Science</i> , 2012, 46, 299-307.	0.5	5
434	Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9â€œGP), a glycoPEGylated recombinant factor IX. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2305-2312.	1.9	58
435	Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2494-2502.	1.9	76
436	PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. <i>Thrombosis Research</i> , 2012, 130, 864-870.	0.8	44
437	Haemophilia B: current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2053-2063.	0.9	22
438	Gene-based continuous expression of FVIIa for the treatment of hemophilia. <i>Frontiers in Bioscience - Scholar</i> , 2012, S4, 287.	0.8	1
439	Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A. <i>Thrombosis and Haemostasis</i> , 2012, 108, 21-31.	1.8	17
440	Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 969-977.	0.8	31
441	Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management. <i>British Journal of Haematology</i> , 2012, 156, 13-23.	1.2	56
442	Aspects of current management: orthopaedic surgery in haemophilia. <i>Haemophilia</i> , 2012, 18, 8-16.	1.0	94
443	Factor IX replacement to cover total knee replacement surgery in haemophilia B: a singleâ€œcentre experience, 2000â€œ2010. <i>Haemophilia</i> , 2012, 18, 46-49.	1.0	27
444	Clinical outcomes and patient satisfaction following total joint replacement in haemophilia â€œ 23â€œyear experience in knees, hips and elbows. <i>Haemophilia</i> , 2012, 18, 86-93.	1.0	63

#	ARTICLE	IF	CITATIONS
445	The influence of prophylactic factor VIII in severe haemophilia A. <i>Haemophilia</i> , 2012, 18, 193-199.	1.0	13
446	Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. <i>Haemophilia</i> , 2012, 18, 369-374.	1.0	62
447	A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center. <i>Haemophilia</i> , 2012, 18, 561-567.	1.0	6
448	Learning intravenous infusion in haemophilia: experience from the Netherlands. <i>Haemophilia</i> , 2012, 18, 516-520.	1.0	31
449	Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. <i>Haemophilia</i> , 2012, 18, 568-574.	1.0	34
450	Quality of life in adult patients with haemophilia – a single centre experience from Sweden. <i>Haemophilia</i> , 2012, 18, 527-531.	1.0	43
451	Haemophilia prophylaxis: how can we justify the costs?. <i>Haemophilia</i> , 2012, 18, 680-684.	1.0	17
452	Is on-demand treatment effective in patients with severe haemophilia?. <i>Haemophilia</i> , 2012, 18, 738-742.	1.0	15
453	Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. <i>Haemophilia</i> , 2012, 18, 760-765.	1.0	61
454	WFH: Closing the global gap – achieving optimal care. <i>Haemophilia</i> , 2012, 18, 1-12.	1.0	86
455	Personalized prophylaxis. <i>Haemophilia</i> , 2012, 18, 131-135.	1.0	80
456	Models of prophylaxis. <i>Haemophilia</i> , 2012, 18, 136-140.	1.0	16
457	Differences between developed and developing countries in paediatric care in haemophilia. <i>Haemophilia</i> , 2012, 18, 94-100.	1.0	18
458	Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. <i>Haemophilia</i> , 2012, 18, 855-859.	1.0	44
459	An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. <i>Haemophilia</i> , 2012, 18, 962-970.	1.0	111
460	Optimizing joint function: new knowledge and novel tools and treatments. <i>Haemophilia</i> , 2012, 18, 17-26.	1.0	6
461	A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 359-367.	1.9	241
462	Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. <i>European Journal of Haematology</i> , 2012, 88, 329-335.	1.1	79

#	ARTICLE	IF	CITATIONS
463	The hope and reality of long-acting hemophilia products. American Journal of Hematology, 2012, 87, S33-9.	2.0	45
464	Guidelines for the management of hemophilia. Haemophilia, 2013, 19, e1-47.	1.0	1,538
465	Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia, 2013, 19, 76-81.	1.0	99
466	Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia (SPINART). Journal of Thrombosis and Haemostasis, 2013, 11, 1119-1127.	1.9	173
467	Treatment for life for severe haemophilia – A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia, 2013, 19, e228-38.	1.0	48
468	Hemophilias and Other Disorders of Hemostasis. , 2013, , 1-33.		12
469	Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opinion on Biological Therapy, 2013, 13, 1287-1297.	1.4	33
470	Use of Clinical Practice Guidelines on Long-term Prophylaxis in Severe Hemophilia in France: A Retrospective Audit. Journal of Pediatrics, 2013, 162, 1241-1244.e1.	0.9	8
471	Hemophilia clinical gene therapy: brief review. Translational Research, 2013, 161, 307-312.	2.2	14
472	Molecular approaches for improved clotting factors for hemophilia. Blood, 2013, 122, 3568-3574.	0.6	40
473	Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies. Blood Reviews, 2013, 27, 103-109.	2.8	17
474	Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia, 2013, 19, 355-361.	1.0	80
475	Assessment of the thrombin generation assay in haemophilia: Comparative study between fresh and frozen platelet-rich plasma. Haemophilia, 2013, 19, 318-321.	1.0	10
476	Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study. Haemophilia, 2013, 19, 727-735.	1.0	26
477	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine, 2013, 369, 2313-2323.	13.9	307
478	The impact of the economic downturn and health care reform on treatment decisions for haemophilia A: patient, caregiver and health care provider perspectives. Haemophilia, 2013, 19, 51-58.	1.0	8
479	Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?. Haemophilia, 2013, 19, 174-180.	1.0	26
480	Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multicentre pilot study in China. Haemophilia, 2013, 19, 27-34.	1.0	60

#	ARTICLE	IF	CITATIONS
481	The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. <i>Haemophilia</i> , 2013, 19, 35-43.	1.0	29
482	The future of hemostasis management. <i>Pediatric Blood and Cancer</i> , 2013, 60, S44-7.	0.8	4
483	Importance of pharmacokinetics in the management of hemophilia. <i>Pediatric Blood and Cancer</i> , 2013, 60, S27-9.	0.8	26
484	Hemophilia and prophylaxis. <i>Pediatric Blood and Cancer</i> , 2013, 60, S23-6.	0.8	21
485	Inherited Abnormalities of Coagulation. <i>Pediatric Clinics of North America</i> , 2013, 60, 1419-1441.	0.9	34
486	Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. <i>Thrombosis Research</i> , 2013, 131, S11-S14.	0.8	34
487	Treatment of hemophilia B: focus on recombinant factor IX. <i>Biologics: Targets and Therapy</i> , 2013, 7, 33.	3.0	27
488	The effect of secondary prophylaxis <i>versus</i> episodic treatment on the range of motion of target joints in patients with haemophilia. <i>British Journal of Haematology</i> , 2013, 161, 424-433.	1.2	21
489	Future of coagulation factor replacement therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 84-98.	1.9	61
490	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. <i>Blood</i> , 2013, 122, 1129-1136.	0.6	200
491	The hemophilias and their clinical management. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 261-267.	0.9	22
492	Tailored versus Standard Dose Prophylaxis in Children with Hemophilia A. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 711-722.	1.5	11
493	Molecular approaches for improved clotting factors for hemophilia. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 30-36.	0.9	11
494	Hemophilia A and Hemophilia B: Different Types of Diseases?. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 697-701.	1.5	29
495	Reversing the action of newer oral anticoagulants. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 14-16.	0.5	0
496	Prevalence and Risk Factors for Hypertension in Hemophilia. <i>Hypertension</i> , 2013, 62, 209-215.	1.3	64
497	Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the <i>UDC</i> database. <i>Haemophilia</i> , 2013, 19, 426-431.	1.0	14
498	Progression of haemophilic arthropathy in children: a Lithuanian <i>vs</i> Danish comparative study. <i>Haemophilia</i> , 2013, 19, 212-218.	1.0	18

#	ARTICLE	IF	CITATIONS
499	Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia. <i>Haemophilia</i> , 2013, 19, 626-631.	1.0	57
500	History of prophylaxis. <i>Haemophilia</i> , 2013, 19, 163-165.	1.0	10
501	Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. <i>Haemophilia</i> , 2013, 19, 790-798.	1.0	102
502	The impact of haemarthropathy on the QoL of Korean severe haemophilia A patients: the critical level of haemarthropathy for the QoL. <i>Haemophilia</i> , 2013, 19, 637-641.	1.0	6
503	Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy. <i>Haemophilia</i> , 2013, 19, 558-563.	1.0	19
504	Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy. <i>Haemophilia</i> , 2013, 19, 808-813.	1.0	30
505	New Advances in the Treatment of Children with Hemophilia. <i>Pediatric and Adolescent Medicine</i> , 2013, , 67-80.	0.4	1
506	Clinical and functional evaluation of the joint status of hemophiliac adults at a Brazilian blood center. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 23-28.	0.7	18
507	Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. <i>Thrombosis and Haemostasis</i> , 2013, 110, 931-939.	1.8	35
510	Climbing therapy under PK-tailored prophylaxis. <i>Hamostaseologie</i> , 2014, 34, S13-S16.	0.9	11
511	Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. <i>Biologics: Targets and Therapy</i> , 2014, 8, 115.	3.0	20
512	Contemporary Approaches to Hemophilia. , 2014, , .		0
513	Pushing the frontiers of medicine: innovations in haemophilia care. <i>Scientific American</i> , 2014, 312, W1-W4.	1.0	1
514	Current Management of the Hemophilic Child: A Demanding Interlocutor. <i>Quality of Life and Adequate Cost-Efficacy Analysis. Pediatric Hematology and Oncology</i> , 2014, 31, 687-702.	0.3	26
520	Hemophilias and Other Disorders of Hemostasis. , 2014, , .		2
521	Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B. <i>Patient Preference and Adherence</i> , 2014, 8, 1073.	0.8	12
522	Lasting power of new clotting proteins. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 355-363.	0.9	10
523	The burden of bleeding in haemophilia: is one bleed too many?. <i>Haemophilia</i> , 2014, 20, 459-463.	1.0	86

#	ARTICLE	IF	CITATIONS
524	Emerging drugs for hemophilia B. Expert Opinion on Emerging Drugs, 2014, 19, 407-414.	1.0	4
525	Correlation between endogenous <sc>VWF</sc>:Ag and <sc>PK</sc> parameters and bleeding frequency in severe haemophilia <sc>A</sc> subjects during threeâ€timesâ€weekly prophylaxis with rFVIIIâ€<sc>FS</sc>. Haemophilia, 2014, 20, e15-22.	1.0	34
526	Knee flexion contracture in haemophilia: treatment with circular external fixator. Haemophilia, 2014, 20, 879-883.	1.0	26
527	Onâ€demand treatment in persons with severe haemophilia. European Journal of Haematology, 2014, 93, 39-47.	1.1	4
528	Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia, 2014, 20, 99-105.	1.0	61
529	<sc>ADVATE</sc> prophylaxis: <i>post hoc</i> analysis of joint bleeding episodes. Haemophilia, 2014, 20, 630-638.	1.0	4
530	Protocol for Oral Implant Rehabilitation in a Hemophilic HIV-Positive Patient With Type C Hepatitis. Implant Dentistry, 2014, 23, 622-625.	1.7	8
531	Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Review of Hematology, 2014, 7, 559-571.	1.0	20
532	Current management of hemophilia B: recommendations, complications and emerging issues. Expert Review of Hematology, 2014, 7, 573-581.	1.0	24
533	Legal requirements for optimal haemophilia treatment in Germany. Thrombosis Research, 2014, 134, S68-S71.	0.8	0
534	Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience. Thrombosis Research, 2014, 134, S27-S32.	0.8	12
535	Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia, 2014, 20, 607-615.	1.0	55
536	Inhibitor development: The last enemy to be defeated in hemophilia A and B. American Journal of Hematology, 2014, 89, 569-570.	2.0	0
537	Patientâ€reported experience of bleeding events in haemophilia. European Journal of Haematology, 2014, 93, 19-28.	1.1	8
538	With blood in the joint â€“ what happens next? Could activation of a proâ€inflammatory signalling axis leading to iRhom2/TNFÎ±â€convertaseâ€dependent release of TNFÎ± contribute to haemophilic arthropathy?. Haemophilia, 2014, 20, 11-14.	1.0	11
539	Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia, 2014, 20, 527-534.	1.0	42
540	Comparison of ultrasound and magnetic resonance imaging for diagnosis and followâ€up of joint lesions in patients with haemophilia. Haemophilia, 2014, 20, e51-7.	1.0	52
541	Longâ€standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of ageâ€matched Danish and Russian patients. Haemophilia, 2014, 20, 58-64.	1.0	16

#	ARTICLE	IF	CITATIONS
542	Prophylaxis in adult patients with severe haemophilia A. <i>Thrombosis Research</i> , 2014, 134, S33-S37.	0.8	8
543	Prophylaxis in real life scenarios. <i>Haemophilia</i> , 2014, 20, 106-113.	1.0	22
544	Methods for individualising factor <scp>VIII</scp> dosing in prophylaxis. <i>European Journal of Haematology</i> , 2014, 93, 16-20.	1.1	31
545	Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensiveâ€”The Example of Hemophilia A. <i>Journal of General Internal Medicine</i> , 2014, 29, 767-773.	1.3	12
547	Multicentre, randomized, openâ€label study of onâ€demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. <i>Haemophilia</i> , 2014, 20, 398-406.	1.0	55
548	BeriateÂ® P in the treatment of patients with haemophilia A: Results of a long-term pharmacovigilance study. <i>Thrombosis Research</i> , 2014, 134, S16-S21.	0.8	1
549	Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats. <i>Thrombosis Research</i> , 2014, 133, 900-907.	0.8	25
550	BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B. <i>Expert Review of Hematology</i> , 2014, 7, 333-342.	1.0	7
551	The knee in severe haemophilia with special emphasis on surgical/invasive procedures. <i>Thrombosis Research</i> , 2014, 134, 545-551.	0.8	7
552	The history of haemophilia â€“ a short review. <i>Thrombosis Research</i> , 2014, 134, S4-S9.	0.8	41
553	A longer acting rFVIII, safe and effective. <i>Blood</i> , 2014, 123, 304-305.	0.6	0
555	The long and short of it: using the new factor products. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 26-32.	0.9	20
556	Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 860-863.	1.5	13
557	Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 396-405.	1.3	14
558	Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies. <i>European Journal of Haematology</i> , 2015, 95, 1-15.	1.1	4
559	Recombinant factorÂVIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophiliaÂA. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 967-977.	1.9	150
560	Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. <i>Blood</i> , 2015, 125, 2038-2044.	0.6	286
561	Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. <i>Thrombosis and Haemostasis</i> , 2015, 114, 35-45.	1.8	87

#	ARTICLE	IF	CITATIONS
562	Prophylaxis in patients with von Willebrand disease: who, when, how?. Journal of Thrombosis and Haemostasis, 2015, 13, 1581-1584.	1.9	14
563	Assessments of outcome in haemophilia – what is the added value of <sc>QoL</sc> tools?. Haemophilia, 2015, 21, 430-435.	1.0	25
564	Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study. Haemophilia, 2015, 21, e369-74.	1.0	21
565	The current status of prophylactic replacement therapy in children and adults with haemophilia. British Journal of Haematology, 2015, 169, 777-786.	1.2	52
566	Unravelling adherence to prophylaxis in haemophilia: a patientsâ€™ perspective. Haemophilia, 2015, 21, 612-621.	1.0	32
567	Experience with central venous access devices (<sc>CVAD</sc>s) in the Canadian hemophilia primary prophylaxis study (<sc>CHPS</sc>). Haemophilia, 2015, 21, 469-476.	1.0	13
568	Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15033.	1.8	2
569	Japanese subject subpopulation analysis of B-LONG: a Phase 3 study of long-acting recombinant factor IX Fc fusion protein. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 420-429.	0.1	1
570	Diagnostic evaluation of our patients with hemophilia A: 17-year experience. Turk Pediatri Arsivi, 2015, 50, 96-101.	0.9	8
571	Pharmacokinetics of plasmaâ€derived vs. recombinant <sc>FVIII</sc> concentrates: a comparative study. Haemophilia, 2015, 21, 204-209.	1.0	22
572	Individualizing prophylaxis in hemophilia: a review. Expert Review of Hematology, 2015, 8, 237-246.	1.0	58
573	Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B. Frontiers of Medicine, 2015, 9, 90-99.	1.5	13
574	Hemophilia Gene Therapy. , 2015, , 207-213.		0
575	Recent Advances in Haemophilia Management. Current Pediatrics Reports, 2015, 3, 154-159.	1.7	2
576	Profile of efralotocog alfa and its potential in the treatment of hemophilia A. Journal of Blood Medicine, 2015, 6, 131.	0.7	9
577	Musculoskeletal Outcome in Hemophilia: Bleeds, Joint Structure and Function, Activity, and Health-Related Fitness. Seminars in Thrombosis and Hemostasis, 2015, 41, 872-879.	1.5	8
578	Switching to recombinant factor <sc>IX</sc> Fc fusion protein prophylaxis results in fewer infusions, decreased factor <sc>IX</sc> consumption and lower bleeding rates. British Journal of Haematology, 2015, 168, 113-123.	1.2	31
579	Various regimens for prophylactic treatment of patients with haemophilia. European Journal of Haematology, 2015, 94, 11-16.	1.1	7

#	ARTICLE	IF	CITATIONS
580	Strategies for reducing inhibitor formation in severe haemophilia. <i>European Journal of Haematology</i> , 2015, 94, 45-50.	1.1	6
581	Safety and pharmacokinetics of anti- κ FPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 743-754.	1.9	195
582	Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. <i>Haemophilia</i> , 2015, 21, 171-179.	1.0	49
583	Longer-acting clotting factor concentrates for hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S167-S175.	1.9	20
584	Joint Surgery in the Adult Patient with Hemophilia. , 2015, , .		7
585	Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 547 187-198.	0.7	17
586	Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. <i>Journal of Blood Medicine</i> , 2016, Volume 7, 275-282.	0.7	16
587	Orthopedic disorders of the knee in hemophilia: A current concept review. <i>World Journal of Orthopedics</i> , 2016, 7, 370.	0.8	32
588	Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. <i>Thrombosis and Haemostasis</i> , 2016, 115, 931-938.	1.8	36
589	Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. <i>Thrombosis and Haemostasis</i> , 2016, 115, 872-895.	1.8	31
590	The Influence of HIV, HCV and Inhibitors on the Quality of Life and Behavior of the Disease in Patients with Haemophilia: An Observational Study. <i>Journal of AIDS & Clinical Research</i> , 2016, 07, .	0.5	0
591	New developments in the management of moderate-to-severe hemophilia B. <i>Journal of Blood Medicine</i> , 2016, 7, 27.	0.7	21
592	Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. <i>Thrombosis and Haemostasis</i> , 2016, 115, 913-920.	1.8	27
593	Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 136-140.	0.5	25
594	Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator. <i>Haemophilia</i> , 2016, 22, 81-86.	1.0	5
595	Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes. <i>Haemophilia</i> , 2016, 22, 218-224.	1.0	42
596	Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use. <i>Haemophilia</i> , 2016, 22, e42-e45.	1.0	4
597	Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 724-732.	1.9	33

#	ARTICLE	IF	CITATIONS
598	Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A. BMC Hematology, 2016, 16, 26.	2.6	5
599	COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA. International Journal of Technology Assessment in Health Care, 2016, 32, 337-347.	0.2	10
601	Musculo-skeletal manifestations of haemophilia. Blood Reviews, 2016, 30, 401-409.	2.8	38
602	An innovative outcome-based care and procurement model of hemophilia management. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 337-345.	0.7	15
603	Social/economic costs and quality of life in patients with haemophilia in Europe. European Journal of Health Economics, 2016, 17, 53-65.	1.4	53
604	Is Continuous Low-Dose Prophylaxis Superior to On-Demand Treatment for Patients with Hemophilia?. Seminars in Thrombosis and Hemostasis, 2016, 42, 533-540.	1.5	6
605	Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Seminars in Thrombosis and Hemostasis, 2016, 42, 018-029.	1.5	19
606	Hemophilia: a cautionary status report. Blood, 2016, 127, 2949-2950.	0.6	0
607	Hemophilia A and B: Diagnosis and Management. , 2016, , 255-262.		0
608	Preventing bleeds by treatment: new era for haemophilia changing the paradigm. Haemophilia, 2016, 22, 9-13.	1.0	8
609	Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia, 2016, 22, e375-82.	1.0	8
610	Dosing regimens, <sc>FVIII</sc> levels and estimated haemostatic protection with special focus on <sc>rFVIII</sc>. Haemophilia, 2016, 22, 389-396.	1.0	33
611	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1105-1109.	1.9	54
612	Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidence. Journal of Internal Medicine, 2016, 279, 502-514.	2.7	8
613	Future of haemophilia outcome assessment: registries are key to optimized treatment. Journal of Internal Medicine, 2016, 279, 498-501.	2.7	11
614	Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia, 2016, 22, 925-933.	1.0	44
615	Emerging drugs for the treatment of hemophilia A and B. Expert Opinion on Emerging Drugs, 2016, 21, 301-313.	1.0	14
616	Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A. Haemophilia, 2016, 22, e401-5.	1.0	5

#	ARTICLE	IF	CITATIONS
617	Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. <i>Haemophilia</i> , 2016, 22, 852-858.	1.0	19
618	The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline. <i>Haemophilia</i> , 2016, 22, 676-683.	1.0	16
619	Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1120-1128.	1.8	13
620	Contemporary issues in the management of von Willebrand disease. <i>Thrombosis and Haemostasis</i> , 2016, 116, S18-S25.	1.8	6
622	Evolution of the Treatments for Hemophilia. <i>Journal of Infusion Nursing</i> , 2016, 39, 218-224.	1.2	5
623	Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?. <i>Thrombosis Journal</i> , 2016, 14, 32.	0.9	28
624	Different impact of factor VIII products on inhibitor development?. <i>Thrombosis Journal</i> , 2016, 14, 31.	0.9	10
625	Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. <i>Haemophilia</i> , 2016, 22, 499-506.	1.0	31
627	Prophylaxis in von Willebrand Disease: Coming of Age?. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 498-506.	1.5	21
628	Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. <i>British Journal of Haematology</i> , 2016, 174, 454-460.	1.2	46
629	The past and future of haemophilia: diagnosis, treatments, and its complications. <i>Lancet, The</i> , 2016, 388, 187-197.	6.3	331
630	Advances and challenges in hemophilic arthropathy. <i>Seminars in Hematology</i> , 2016, 53, 10-19.	1.8	85
631	Factor VIII/factor IX prophylaxis for severe hemophilia. <i>Seminars in Hematology</i> , 2016, 53, 3-9.	1.8	19
632	Bone and Joint Deformity in Metabolic, Inflammatory, Neoplastic, Infectious, and Hematologic Disorders. , 2016, , 411-504.		0
633	Pharmacokinetics, tissue distribution and excretion of 40kDa PEG and PEGylated rFVIII (N8-GP) in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 87, 58-68.	1.9	24
634	Primary prophylaxis in haemophilia care: Guideline update 2016. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 81-85.	0.6	29
635	Inhibitor screening in non-severe haemophilia patients; a major challenge. <i>British Journal of Haematology</i> , 2017, 176, 683-685.	1.2	1
636	Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. <i>Blood</i> , 2017, 129, 2368-2374.	0.6	121

#	ARTICLE	IF	CITATIONS
637	Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. <i>Haemophilia</i> , 2017, 23, 422-429.	1.0	7
638	Pathophysiology of hemophilic arthropathy and potential targets for therapy. <i>Pharmacological Research</i> , 2017, 115, 192-199.	3.1	93
639	Progress in the contemporary management of hemophilia: The new issue of patient aging. <i>European Journal of Internal Medicine</i> , 2017, 43, 16-21.	1.0	26
640	From treatment to prevention of bleeds: what more evidence do we need?. <i>Haemophilia</i> , 2017, 23, 494-496.	1.0	1
641	Low-dose prophylaxis for children with haemophilia in a resource-limited setting in south India: A clinical audit report. <i>Haemophilia</i> , 2017, 23, e382-e384.	1.0	18
642	If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1103-1105.	1.9	12
643	Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates. <i>Haemophilia</i> , 2017, 23, 566-574.	1.0	49
644	Predictors of quality of life among adolescents and young adults with a bleeding disorder. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 67.	1.0	25
645	The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 851-858.	0.7	14
646	The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China. <i>Expert Review of Hematology</i> , 2017, 10, 995-1004.	1.0	24
647	Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. <i>Blood</i> , 2017, 130, 2463-2468.	0.6	197
648	Effect of late prophylaxis in hemophilia on joint status: a randomized trial. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2115-2124.	1.9	95
649	Gender related issues in thrombosis and hemostasis. <i>Expert Review of Hematology</i> , 2017, 10, 941-949.	1.0	14
650	Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 425-430.	0.5	21
651	PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. <i>Thrombosis Research</i> , 2017, 157, 58-63.	0.8	43
652	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment. <i>British Journal of Haematology</i> , 2017, 179, 298-307.	1.2	56
653	Prophylaxis use among males with haemophilia B in the United States. <i>Haemophilia</i> , 2017, 23, 910-917.	1.0	8
654	Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience. <i>Haemophilia</i> , 2017, 23, e403-e408.	1.0	5

#	ARTICLE	IF	CITATIONS
655	Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 819-828.	13.9	292
656	The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A. <i>Thrombosis and Haemostasis</i> , 2017, 117, 277-285.	1.8	6
657	A cross-sectional analysis of joint status and quality of life in children and adolescents with haemophilia in Romania. <i>Hamostaseologie</i> , 2017, 37, S5-S8.	0.9	1
658	The History of Clotting Factor Concentrates Pharmacokinetics. <i>Journal of Clinical Medicine</i> , 2017, 6, 35.	1.0	11
659	Classical Bleeding Disease (Hemophilia). , 2017, , 1-14.		1
660	Treatment adherence in hemophilia. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1677-1686.	0.8	117
661	Should Arterial Embolization in Recurrent Spontaneous Hemophilic Hemarthroses Refractory to Intensive Prophylaxis be the First Invasive Resort?. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2017, 17, 33-37.	0.2	0
662	Hemophilic Arthropathy. , 2017, , 2007-2017.		2
663	Long-term clinical and economic outcomes in previously untreated paediatric patients with severe haemophilia A: A nationwide real-world study with 700 person-years. <i>Haemophilia</i> , 2018, 24, 436-444.	1.0	7
664	Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica. <i>Haemophilia</i> , 2018, 24, e230-e241.	1.0	11
665	Defining extended half-life $rFVIII$ —A critical review of the evidence. <i>Haemophilia</i> , 2018, 24, 348-358.	1.0	62
666	Management of Hemophilic Cysts and Pseudotumors of the Hand in Bleeding Disorders: A Case Series. <i>Journal of Hand Surgery</i> , 2018, 43, 486.e1-486.e9.	0.7	5
667	Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B. <i>Haemophilia</i> , 2018, 24, 253-260.	1.0	14
668	In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A. <i>Cell Transplantation</i> , 2018, 27, 130-139.	1.2	19
669	Individualized PK-based prophylaxis in severe haemophilia. <i>Haemophilia</i> , 2018, 24, 3-17.	1.0	28
670	Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 513-518.	0.7	13
671	Major bleeding disorders: diagnosis, classification, management and recent developments in haemophilia. <i>Archives of Disease in Childhood</i> , 2018, 103, 509-513.	1.0	5
672	Breakthrough bleeding in relation to pharmacokinetics of Factor $VIII$ in paediatric patients with severe haemophilia A. <i>Haemophilia</i> , 2018, 24, 120-125.	1.0	3

#	ARTICLE	IF	CITATIONS
673	Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patients. <i>Health Psychology and Behavioral Medicine</i> , 2018, 6, 277-300.	0.8	4
674	Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A. <i>Chinese Medical Journal</i> , 2018, 131, 1780-1785.	0.9	10
675	Inhibitor clinical burden of disease: a comparative analysis of the CHES data. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 198.	1.2	15
676	Self-reported activity of Swedish persons with haemophilia: Change over 2.5 years. <i>Journal of Rehabilitation Medicine</i> , 2018, 50, 643-651.	0.8	4
677	Impact of intermediateâ€¦dose prophylaxis on progression of haemarthropathy in patients with severe haemophilia A: A 10â€¦year, singleâ€¦centre experience in Korea. <i>Haemophilia</i> , 2018, 24, e402-e409.	1.0	0
678	The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2362-2374.	1.9	50
679	Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab. <i>Drugs</i> , 2018, 78, 881-890.	4.9	38
680	Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq^{Â®} (humanâ€¦rh<scp>FVIII</scp>) in previously treated patients with severe haemophilia A. <i>Haemophilia</i> , 2018, 24, 619-627.	1.0	22
681	Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010. <i>Haemophilia</i> , 2018, 24, 964-970.	1.0	5
682	Optimizing bleed prevention throughout the lifespan: Womb to Tomb. <i>Haemophilia</i> , 2018, 24, 76-86.	1.0	4
683	Prophylaxis reâ€¦visited: The potential impact of novel factor and nonâ€¦factor therapies on prophylaxis. <i>Haemophilia</i> , 2018, 24, 845-848.	1.0	5
684	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. <i>Lancet Haematology</i> , 2018, 5, e252-e260.	2.2	31
685	The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. <i>Thrombosis Research</i> , 2018, 170, 53-59.	0.8	4
686	Prevention and Management of Bleeding Episodes in Children with Hemophilia. <i>Paediatric Drugs</i> , 2018, 20, 455-464.	1.3	13
687	The benefits of prophylaxis in patients with hemophilia B. <i>Expert Review of Hematology</i> , 2018, 11, 673-683.	1.0	42
688	Increased bone resorption in hemophilia. <i>Blood Reviews</i> , 2019, 33, 6-10.	2.8	28
689	Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status. <i>Blood Reviews</i> , 2019, 33, 106-116.	2.8	12
690	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. <i>Blood</i> , 2019, 134, 317-320.	0.6	71

#	ARTICLE	IF	CITATIONS
691	HAEMOCare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries. <i>TH Open</i> , 2019, 03, e190-e199.	0.7	14
692	Antibodies in the Treatment of Haemophilia A – A Biochemical Perspective. <i>Hamostaseologie</i> , 2019, 39, 036-041.	0.9	2
693	Comprehensive care for hemophilia and other inherited bleeding disorders. <i>Transfusion and Apheresis Science</i> , 2019, 58, 565-568.	0.5	10
694	Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A. <i>Thrombosis Research</i> , 2019, 183, 1-3.	0.8	9
695	Bleed volume of experimental knee haemarthrosis correlates with the subsequent degree of haemophilic arthropathy. <i>Haemophilia</i> , 2019, 25, 324-333.	1.0	8
696	Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 184-201.	1.8	39
697	Moderate haemophilia in focus. <i>Haemophilia</i> , 2019, 25, 187-188.	1.0	6
698	Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B. <i>Haemophilia</i> , 2019, 25, e247-e256.	1.0	6
699	52 year Male with Haemophilia-A; Presented with Scrotal Haematoma: Managed in Resource Constraint Settings - A Case Report. <i>Journal of Shaheed Suhrawardy Medical College</i> , 2019, 10, 118-121.	0.1	1
700	Novel Piperazino-Enaminones Decrease Pro-inflammatory Cytokines Following Hemarthrosis in a Hemophilia Mouse Model. <i>Inflammation</i> , 2019, 42, 1719-1729.	1.7	2
701	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 427-438.	0.8	8
702	Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children. <i>Haemophilia</i> , 2019, 25, 633-639.	1.0	22
703	Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A. <i>Haemophilia</i> , 2019, 25, 408-415.	1.0	10
704	Risks and patient outcomes of surgical intervention for hemophilic arthropathy. <i>Expert Review of Hematology</i> , 2019, 12, 325-333.	1.0	11
705	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. <i>Blood Advances</i> , 2019, 3, 3241-3247.	2.5	85
706	Adherence to prophylactic treatment. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, S19-S21.	0.5	2
707	Limitations of prophylactic treatment in patients with hemophilia. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, S22-S24.	0.5	2
708	New therapies for hemophilia. <i>Blood</i> , 2019, 133, 389-398.	0.6	120

#	ARTICLE	IF	CITATIONS
709	Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. <i>Haemophilia</i> , 2019, 25, 205-212.	1.0	51
710	Over two decades of orthopaedic surgery in patients with inhibitorsâ€”Quantifying the complication of bleeding. <i>Haemophilia</i> , 2019, 25, 21-32.	1.0	2
712	Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. <i>International Journal of Hematology</i> , 2020, 111, 42-50.	0.7	40
713	Hemophilia â€” Impact of Recent Advances on Management. <i>Indian Journal of Pediatrics</i> , 2020, 87, 134-140.	0.3	3
714	Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy. <i>Current Medical Research and Opinion</i> , 2020, 36, 9-15.	0.9	23
715	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (AdynovateÂ®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. <i>Clinical Pharmacokinetics</i> , 2020, 59, 245-256.	1.6	18
716	Extended half-life recombinant products in haemophilia clinical practice â€” Expectations, opportunities and challenges. <i>Thrombosis Research</i> , 2020, 196, 609-617.	0.8	18
717	Comparison of different prophylactic regimens for Thai children with moderate and severe haemophilia A. <i>Haemophilia</i> , 2020, 26, e211-e213.	1.0	1
718	Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B â€” The MoHem study. <i>Haemophilia</i> , 2020, 26, 891-897.	1.0	23
719	A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. <i>Pilot and Feasibility Studies</i> , 2020, 6, 189.	0.5	8
720	The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. <i>American Journal of Hematology</i> , 2020, 95, 960-965.	2.0	19
721	Show me the evidence: Effectiveness of low-dose prophylaxis. <i>Haemophilia</i> , 2020, 26, 9-10.	1.0	7
722	Prophylaxis for hemophilia A without inhibitors: treatment options and considerations. <i>Expert Review of Hematology</i> , 2020, 13, 731-743.	1.0	16
723	Impact of treatment regimen with moroctocog alfa (AFâ€”CC) on bleeding rates in paediatric patients with severe haemophilia A. <i>Haemophilia</i> , 2020, 26, e232-e235.	1.0	0
724	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 728-736.	1.8	19
725	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. <i>Blood Advances</i> , 2020, 4, 2451-2459.	2.5	67
726	Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly. <i>Reports</i> , 2020, 3, 3.	0.2	0
727	Joint scores in hemophilic arthropathy in children: Developing country perspectives. <i>European Journal of Rheumatology</i> , 2020, 7, 26-30.	1.3	7

#	ARTICLE	IF	CITATIONS
728	FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1586-1597.	1.9	2
729	Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1242-1255.	1.9	32
730	Global coagulation assays in hemophilia A: A comparison to conventional assays. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 298-308.	1.0	12
731	Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 469-481.	2.0	11
732	Is Low Dose a New Dose to Initiate Hemophilia A Prophylaxis? – A Systematic Study in Eastern India. <i>Indian Journal of Pediatrics</i> , 2020, 87, 345-352.	0.3	10
733	Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 303-309.	1.9	16
734	Redefining prophylaxis in the modern era. <i>Haemophilia</i> , 2021, 27, 21-27.	1.0	8
735	Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns. <i>Haemophilia</i> , 2021, 27, 103-113.	1.0	28
736	Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015. <i>Thrombosis Research</i> , 2021, 198, 196-203.	0.8	5
737	The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. <i>Lancet, The</i> , 2021, 397, 630-640.	6.3	71
738	Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. <i>Haemophilia</i> , 2021, 27, e253-e259.	1.0	10
739	Which tests can most effectively indicate the clinical phenotype of paediatric haemophilia patients with prophylaxis?. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 259-265.	0.5	2
740	Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A. <i>Haemophilia</i> , 2021, 27, 237-244.	1.0	5
742	Ultrasound and magnetic resonance imaging for the detection of blood: An ex vivo study. <i>Haemophilia</i> , 2021, 27, 488-493.	1.0	5
743	A comparison of MyPKFit and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa. <i>Haemophilia</i> , 2021, 27, 417-424.	1.0	7
744	Practical considerations for nonfactor replacement therapies in the treatment of haemophilia with inhibitors. <i>Haemophilia</i> , 2021, 27, 340-350.	1.0	15
745	Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A. <i>Pediatric Investigation</i> , 2021, 5, 38-45.	0.6	7
746	Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged < 12 years with severe hemophilia A. <i>Haemophilia</i> , 2021, 27, e340-e346.	1.0	0

#	ARTICLE	IF	CITATIONS
747	Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (Hâ€FIT). Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12519.	1.0	1
748	Realâ€world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal followâ€up in a national adult cohort. Haemophilia, 2021, 27, 618-625.	1.0	9
749	Pharmacokineticâ€guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia, 2021, 27, e450-e457.	1.0	10
750	Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study. BMJ Open, 2021, 11, e048432.	0.8	1
751	Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A. Journal of Pediatrics, 2021, 234, 212-219.e3.	0.9	1
752	Current therapeutic approaches in the management of hemophiliaâ€a consensus view by the Romanian Society of Hematology. Annals of Translational Medicine, 2021, 9, 1091-1091.	0.7	7
753	Considerations on activity assay discrepancies in factor VIII and factor IX products. Journal of Thrombosis and Haemostasis, 2021, 19, 2102-2111.	1.9	4
754	Low dose long-acting factor VIII prophylaxis in pediatric and young adult patients with hemophilia A: Short-term single-center experience from a developing country. , 0, .		1
755	Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized lowâ€dose secondary prophylaxis study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12552.	1.0	5
756	Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. The Cochrane Library, 2021, 2021, CD014201.	1.5	5
757	Evolution of clotting factor concentrates prescriptions and impact of recommendations of prophylaxis in children with haemophilia. Therapie, 2021, 76, 23-29.	0.6	1
758	Some Discussion Essentials for Musculoskeletal Care and Prior to Joint Replacement. , 0, , 218-226.		2
759	Radiosynoviorthesis in Patients with Haemophilia and Inhibitors. , 0, , 129-131.		3
761	Quality of Life in Hemophilia. , 2010, , 1895-1920.		25
762	Use of Prophylaxis to Prevent Complications of Hemophilia. Advances in Experimental Medicine and Biology, 2001, 489, 59-64.	0.8	13
763	Knee Surgery in Hemophilia. , 2015, , 57-65.		2
764	Orthopedic Surgery in Patients with Hemophilia. , 2008, , .		1
766	Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia, 2001, 7, 117-122.	1.0	22

#	ARTICLE	IF	CITATIONS
767	What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?. Haemophilia, 2001, 7, 99-102.	1.0	83
768	Methods to treat chronic haemophilic synovitis. Haemophilia, 2001, 7, 1-5.	1.0	41
769	Symposium in memory of Professor Inga Marie Nilsson. Haemophilia, 2001, 7, 401-410.	1.0	1
770	Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia, 2001, 7, 392-396.	1.0	203
771	Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 910-4.	0.7	9
772	Minimizing Joint Damage. Orthopaedic Nursing, 2010, 29, 193-200.	0.2	13
773	Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the <scp>MUSFIH</scp> study. Haemophilia, 2017, 23, 538-546.	1.0	20
774	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. Journal of Thrombosis and Haemostasis, 2013, 11, 670-678.	1.9	150
775	High cost, low volume care: the case of haemophilia. BMJ: British Medical Journal, 1997, 315, 962-963.	2.4	9
776	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. Hematology American Society of Hematology Education Program, 2000, 2000, 241-265.	0.9	9
777	Orthopaedic Status and Surgical Needs of Patients with Haemophilia in Algeria. Open Journal of Hematology, 2013, 4, 1.	0.4	3
778	Persons with Haemophilia in Sweden- Experiences and Strategies in Everyday Life. A Single Centre Study. PLoS ONE, 2015, 10, e0139690.	1.1	23
779	The role of the European haemophilia nurse. The Journal of Haemophilia Practice, 2013, 1, 24-27.	0.2	8
780	Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics: Targets and Therapy, 2009, 3, 117.	3.0	15
781	Primary prophylaxis in children with haemophilia. Blood Transfusion, 2008, 6 Suppl 2, s4-11.	0.3	18
782	Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?. Blood Transfusion, 2013, 11, 364-9.	0.3	25
783	Clinical use of factor VIII and factor IX concentrates. Blood Transfusion, 2013, 11 Suppl 4, s55-63.	0.3	16
784	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion, 2014, 12, 575-98.	0.3	52

#	ARTICLE	IF	CITATIONS
785	Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. <i>Blood Transfusion</i> , 2014, 12, 314-9.	0.3	46
786	Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. <i>Blood Transfusion</i> , 2020, 18, 152-158.	0.3	8
787	Diagnostic accuracy of haemophilia early arthropathy detection with ultrasound (HEAD-US): a comparative magnetic resonance imaging (MRI) study. <i>Radiology and Oncology</i> , 2019, 53, 178-186.	0.6	29
788	A multi-center post-marketing surveillance study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2005, 16, 650-663.	0.1	1
789	Title is missing!. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2008, 19, 510-519.	0.1	7
790	2013 revised edition : hemostatic treatment guidelines for hemophilia patients without inhibitors. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2013, 24, 619-639.	0.1	11
791	Study to evaluate the effectiveness of coagulation factor concentrate prophylaxis in children with severe hemophilia. <i>Indian Journal of Child Health</i> , 2017, 4, 35-38.	0.2	1
792	Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea. <i>Korean Journal of Pediatrics</i> , 2013, 56, 291.	1.9	2
793	The Efficiency of Substitutive Treatment with Moroctocog Alfa in Managing Hemostasis in Patients with Hemophilia A Without Inhibitors With Total Knee Arthroplasties. <i>Revista De Chimie (discontinued)</i> , 2019, 69, 3702-3704.	0.2	2
795	Synovectomy using samarium-153 hydroxyapatite in the elbows and ankles of patients with hemophilic arthropathy. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 6-11.	0.3	7
796	Hemophilic Arthropathy. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2004, 12, 234-245.	1.1	179
797	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 241-265.	0.9	1
798	Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. <i>Blood</i> , 2000, 96, 1698-1702.	0.6	3
799	Epiphyseal Involvement with Metabolic, Inflammatory, Neoplastic, Infectious, and Hematologic Disorders. , 2001, , 872-933.		0
800	Title is missing!. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2004, 15, 522-534.	0.1	2
801	Neue Behandlungskonzepte durch Gentherapie. , 2004, , 2010-2019.		0
802	Long-term Care of Children with Hemophilia. , 2005, , 1075-1080.		0
803	Kogenate [®] 1/2FS: antihemophilic factor rFVIII-FS. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 699-708.	0.2	0

#	ARTICLE	IF	CITATIONS
805	Optimal treatment for children with haemophilia: a review. Acta Medica Lituanica, 2009, 16, 15-22.	0.2	0
806	Introductionâ€”Quality of life in patients with congenital hemophilia and inhibitors. Japanese Journal of Thrombosis and Hemostasis, 2010, 21, 475-476.	0.1	0
807	Bilateral total knee arthroplasty in a patient with hemophilia A, high inhibitor titre and aneurysma spurium of the popliteal artery. Swiss Medical Weekly, 2010, 140, w13094.	0.8	8
808	Hemophilia and vonWillebrand disease. , 2011, , 1913-1920.e1.		1
809	The Hemophilic Joints. Journal of Blood Disorders & Transfusion, 2011, 02, .	0.1	0
818	Hemophilic Arthropathy. , 2013, , 1915-1923.		0
819	Osteochondrosis or Epiphysitis and Other Miscellaneous Affections. , 2013, , 1133-1199.e10.		0
821	Die Arthropathie bei hÃmophilen Jugendlichen und Erwachsenen in den neuen BundeslÃndern. , 1993, , 110-115.		0
822	Clinical and Radiological Features of Chronic Arthropathy in Haemophiliacs - Correlation with the Type of Treatment and Therapeutic Approach. , 1997, , 294-305.		0
823	PrÃvention der hÃmophilen Arthropathie durch Prophylaxe im Kindesalter. , 1998, , 19-25.		0
824	Approaches to funding: Swedish cost-effectiveness study. Haemophilia, 1998, 4, 10-12.	1.0	3
825	Diagnostik, Klinik und Therapie der HÃmophilie A und B. , 1999, , 185-197.		0
826	Hematological Concepts and Hematological Perioperative Treatment. , 2015, , 13-19.		0
827	Shoulder Surgery in Hemophilia. , 2015, , 37-42.		0
828	Hemophilia and von Willebrand disease. , 2015, , 1615-1622.		2
829	Health-related quality of life of partners of adults with haemophilia. The Journal of Haemophilia Practice, 2015, 2, 20-26.	0.2	0
830	Extended half life coagulation products for hemophilia. Japanese Journal of Thrombosis and Hemostasis, 2017, 28, 472-479.	0.1	1
831	Efficacy and safety of the drug Octofactor in prophylactic treatment in patients with severe haemophilia A. Russian Journal of Pediatric Hematology and Oncology, 2018, 5, 60-73.	0.1	3

#	ARTICLE	IF	CITATIONS
832	HEMOPHILIA PATIENT WITH DIFFICULTY IN BLOOD PRESSURE CONTROL. Sanamed, 2018, 13, 305.	0.1	0
833	Optimal Management of Elective Joint Replacement Surgery in Patients with Hemophilia. , 0, , .		0
834	Functional Independence Score in Haemophilia: A Hospital Based Observational Study in a Tertiary Care Center in Central India. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 2702-2705.	0.0	2
835	Outcomes of 1.8-3.0 mm incision phacoemulsification combined with trabeculectomy for primary angle-closure glaucoma with cataract. International Journal of Ophthalmology, 2020, 13, 246-251.	0.5	1
836	Magnetic resonance imaging in boys with severe hemophilia A: Serial and endâ€ofâ€study findings from the Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12565.	1.0	4
837	Orthopedic Surgery in HIV-Positive Hemophiliac Patients. , 2008, , 23-32.		0
838	Neue Behandlungskonzepte durch Gentherapie. , 2007, , 2068-2079.		0
841	Physiotherapy for Adult Patients with Haemophilia. , 0, , 177-186.		7
842	Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada. Cmaj, 1995, 153, 147-57.	0.9	1
843	Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vascular Health and Risk Management, 2007, 3, 527-31.	1.0	29
845	Prophylaxis in congenital coagulation disorders: past, present and future. Blood Transfusion, 2008, 6 Suppl 2, s1-3.	0.3	1
846	Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfusion, 2008, 6 Suppl 2, s17-20.	0.3	8
847	Target of prophylaxis in severe haemophilia: more than factor levels. Blood Transfusion, 2013, 11, 327-9.	0.3	11
848	Haemophilia Centre certification system across Europe: the Belgian experience. Blood Transfusion, 2014, 12 Suppl 3, s497-500.	0.3	5
849	Current and evolving features in the clinical management of haemophilia. Blood Transfusion, 2014, 12 Suppl 3, s554-62.	0.3	4
852	Impact of Pharmacokinetics to Reduce Bleeding in a Cohort of Patients with Severe Hemophilia A in a Personalized Comprehensive Management Program. Hematology Reports, 2021, 13, 8904.	0.3	4
853	Hemophilia: The Past, the Present, and the Future. Pediatrics in Review, 2021, 42, 672-683.	0.2	3
854	Bone mineral density in haemophilia â€“ a multicentre study evaluating the impact of different replacement regimens. Haemophilia, 2022, 28, 239-246.	1.0	2

#	ARTICLE	IF	CITATIONS
855	Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973. <i>Haemophilia</i> , 2022, 28, 223-229.	1.0	2
856	Improved clinical outcome after PK-Guided Personalised Prophylaxis with my-PKFIT [®] in patients with hemophilia A without inhibitors. <i>Medical Science and Discovery</i> , 2022, 9, .	0.1	0
857	Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12686.	1.0	4
858	Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A. <i>Thrombosis Research</i> , 2022, 213, 71-77.	0.8	5
859	Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention. <i>Healthcare (Switzerland)</i> , 2021, 9, 1702.	1.0	2
861	Impact of novel hemophilia therapies around the world. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12695.	1.0	19
862	Low-dose prophylaxis and its impact on the health of haemophilia patients. <i>Vox Sanguinis</i> , 2022, , .	0.7	3
869	Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia. <i>Haemophilia</i> , 2022, 28, 26-34.	1.0	6
870	Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience. <i>Haemophilia</i> , 2022, , .	1.0	1
871	The potential role of protease systems in hemophilic arthropathy. <i>Blood Advances</i> , 2022, 6, 5505-5515.	2.5	3
872	Prominent Mutation of Intron 22 Inversion in Sporadic Hemophilia: Is It Worth the Antenatal Screening?. <i>The Application of Clinical Genetics</i> , 0, Volume 15, 49-54.	1.4	1
874	Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 3345.	1.0	2
875	Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. <i>Thrombosis Research</i> , 2022, 216, 35-42.	0.8	4
876	Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia in China. <i>Advances in Therapy</i> , 2022, 39, 3777-3788.	1.3	4
877	Osteoporosis in hemophilia: what is its importance in clinical practice?. <i>Expert Review of Hematology</i> , 0, , 1-14.	1.0	2
878	Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future. <i>Expert Review of Hematology</i> , 0, , 1-11.	1.0	0
879	Disorders of Hemostasis and Thrombosis. , 2023, , 173-211.		0
880	Adeno-Associated Virus Gene Therapy for Hemophilia. <i>Annual Review of Medicine</i> , 2023, 74, 231-247.	5.0	26

#	ARTICLE	IF	CITATIONS
881	Needs of people with rare diseases that can be supported by electronic resources: a scoping review. <i>BMJ Open</i> , 2022, 12, e060394.	0.8	7
882	The value of radiosynoviorthesis for treatment of chronic synovitis in haemophilic joint disease. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	0.4	0
883	The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients. <i>TH Open</i> , 2022, 06, e365-e377.	0.7	1
884	Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A. <i>Journal of Medicine and Life</i> , 2022, 15, 570-578.	0.4	4
885	Primary prophylaxis in children with severe haemophilia A and Bâ€”Implementation over the last 20 years as illustrated in realâ€”world data in the PedNet cohorts. <i>Haemophilia</i> , 2023, 29, 498-504.	1.0	2
886	Haemophilia A and B â€” evaluation of the Swedish prophylactic regimen by magnetic resonance imaging. <i>Haemophilia</i> , 2023, 29, 193-198.	1.0	3
887	Long-term prophylaxis: what are our options and how to define success?. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 579-585.	0.9	4
888	Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100005.	1.0	4
889	BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial. <i>Thrombosis and Haemostasis</i> , 2023, 123, 027-039.	1.8	0
890	High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100061.	1.0	1
891	Another Victory for Patients with Hemophilia. <i>New England Journal of Medicine</i> , 2023, 388, 372-373.	13.9	3
892	Race, ethnicity, F8 variants, and inhibitor risk: analysis of the â€œMy Life Our Futureâ€”hemophilia A database. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 800-813.	1.9	3
893	Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100077.	1.0	1
894	Growing weapons to fight hemophilia. , 2023, 2, .		0
895	New directions to develop therapies for people with hemophilia. <i>Expert Review of Hematology</i> , 2023, 16, 417-433.	1.0	4
896	Decline in healthâ€”related quality of life and foot and ankle patient reported outcomes measures in patients with haemophilia and ankle haemarthropathy. <i>Journal of Foot and Ankle Research</i> , 2023, 16, .	0.7	0
897	Update on the Treatment of Haemophilia A. <i>Advances in Clinical Medicine</i> , 2023, 13, 3973-3978.	0.0	0